RAJSREESUGSugar
Rajshree Sugars & Chemicals Ltd — Profit & Loss Statement
₹28.29
-4.00%
Rajshree Sugars & Chemicals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 1.20 Cr | 0.46 Cr | — |
| Tax Rate For Calcs | 0.27 | 0.35 | 0.30 | 0.30 | — |
| Normalized EBITDA | 50.50 Cr | 68.44 Cr | 54.98 Cr | 41.60 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 4.01 Cr | 1.53 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 4.01 Cr | 1.53 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 8.09 Cr | 13.76 Cr | -8.97 Cr | -3.18 Cr | — |
| Reconciled Depreciation | 23.46 Cr | 23.65 Cr | 24.21 Cr | 24.11 Cr | — |
| Reconciled Cost Of Revenue | 471.37 Cr | 553.02 Cr | 593.58 Cr | 344.39 Cr | — |
| EBITDA | 50.50 Cr | 68.44 Cr | 58.99 Cr | 43.13 Cr | — |
| EBIT | 27.05 Cr | 44.79 Cr | 34.78 Cr | 19.03 Cr | — |
| Net Interest Income | -15.97 Cr | -23.73 Cr | -13.12 Cr | -19.77 Cr | — |
| Interest Expense | 15.97 Cr | 23.73 Cr | 14.05 Cr | 21.63 Cr | — |
| Normalized Income | 8.09 Cr | 13.76 Cr | -11.78 Cr | -4.25 Cr | — |
| Net Income From Continuing And Discontinued Operation | 8.09 Cr | 13.76 Cr | -8.97 Cr | -3.18 Cr | — |
| Total Expenses | 626.52 Cr | 731.59 Cr | 736.80 Cr | 459.49 Cr | — |
| Diluted Average Shares | 3.32 Cr | 3.32 Cr | 3.31 Cr | 3.19 Cr | — |
| Basic Average Shares | 3.32 Cr | 3.32 Cr | 3.31 Cr | 3.19 Cr | — |
| Diluted EPS | 2.44 | 4.15 | -2.71 | -0.96 | — |
| Basic EPS | 2.44 | 4.15 | -2.71 | -0.96 | — |
| Diluted NI Availto Com Stockholders | 8.09 Cr | 13.76 Cr | -8.97 Cr | -3.18 Cr | — |
| Net Income Common Stockholders | 8.09 Cr | 13.76 Cr | -8.97 Cr | -3.18 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 8.09 Cr | 13.76 Cr | -8.97 Cr | -3.18 Cr | — |
| Net Income Including Noncontrolling Interests | 8.09 Cr | 13.76 Cr | -8.97 Cr | -3.18 Cr | — |
| Net Income Continuous Operations | 8.09 Cr | 13.76 Cr | -8.97 Cr | -3.18 Cr | — |
| Tax Provision | 2.98 Cr | 7.30 Cr | 29.70 Cr | 0.58 Cr | — |
| Pretax Income | 11.08 Cr | 21.06 Cr | 20.73 Cr | -2.60 Cr | — |
| Other Non Operating Income Expenses | 11.75 Cr | 12.73 Cr | 1.95 Cr | 7.75 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 4.01 Cr | 1.53 Cr | — |
| Net Non Operating Interest Income Expense | -15.97 Cr | -23.73 Cr | -13.12 Cr | -19.77 Cr | — |
| Interest Expense Non Operating | 15.97 Cr | 23.73 Cr | 14.05 Cr | 21.63 Cr | — |
| Operating Income | 15.29 Cr | 32.06 Cr | 27.89 Cr | 7.88 Cr | — |
| Operating Expense | 155.15 Cr | 178.58 Cr | 143.22 Cr | 115.10 Cr | — |
| Other Operating Expenses | 84.24 Cr | 104.92 Cr | 72.45 Cr | 52.22 Cr | — |
| Depreciation And Amortization In Income Statement | 23.46 Cr | 23.65 Cr | 24.21 Cr | 24.11 Cr | — |
| Depreciation Income Statement | 23.46 Cr | 23.65 Cr | 24.21 Cr | 24.11 Cr | — |
| Gross Profit | 170.45 Cr | 210.63 Cr | 171.11 Cr | 122.98 Cr | — |
| Cost Of Revenue | 471.37 Cr | 553.02 Cr | 593.58 Cr | 344.39 Cr | — |
| Total Revenue | 641.82 Cr | 763.65 Cr | 764.69 Cr | 467.37 Cr | — |
| Operating Revenue | 641.82 Cr | 763.65 Cr | 764.69 Cr | 467.37 Cr | — |
| Interest Income | — | 3.53 Cr | 1.07 Cr | 2.42 Cr | 0.51 Cr |
| Rent Expense Supplemental | — | 0.22 Cr | 0.06 Cr | 0.22 Cr | 0.22 Cr |
| Other Special Charges | — | -0.45 Cr | -4.01 Cr | -1.53 Cr | -3.96 Cr |
| Total Other Finance Cost | — | 0.26 Cr | 0.14 Cr | 0.56 Cr | 0.02 Cr |
| Interest Income Non Operating | — | 3.53 Cr | 1.07 Cr | 2.42 Cr | 0.51 Cr |
| Selling General And Administration | — | 6.68 Cr | 6.94 Cr | 4.99 Cr | 4.78 Cr |
| Selling And Marketing Expense | — | 4.21 Cr | 4.86 Cr | 3.05 Cr | 2.74 Cr |
| General And Administrative Expense | — | 2.46 Cr | 2.08 Cr | 1.94 Cr | 2.05 Cr |
| Rent And Landing Fees | — | 0.22 Cr | 0.06 Cr | 0.22 Cr | 0.22 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Rajshree Sugars & Chemicals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.